Conventional therapeutics, whether small-molecule inhibitors or monoclonal antibodies, bind to oncogenic proteins and block their catalytic activity or extracellular portions. Yet many disease-driving proteins in breast cancer lack enzymatic functions, acting instead through scaffolding or transcription-regulator roles with extensive flat or disordered binding interfaces that conventional inhibitors cannot engage. Targeted protein degradation represents a paradigm change: rather than temporarily silencing a protein’s activity, PROTACs remove the protein entirely from the cellular setting by exploiting the ubiquitin-proteasome system, the cell’s central quality-control machinery. This approach achieves both functional silencing and complete protein elimination over time, potentially eliminating all catalytic and non-catalytic effects and circumventing adaptive resistance through pathway recovery.

PROTACs are bifunctional molecules comprising a warhead that binds the protein of interest, a ligand that recruits an E3 ubiquitin ligase, and a linker joining the two. Upon binding, the PROTAC acts as a molecular bridge, facilitating formation of a transient ternary complex of PROTAC, E3 ligase, and target protein. Productive ternary-complex formation positions the target for ubiquitin transfer through the E1-E2-E3 enzymatic cascade, resulting in polyubiquitination and recognition by the 26S proteasome. Because the molecule is event-driven, it can engage in sequential rounds of degradation, producing long-lasting effects from sub-stoichiometric exposures. The composition and stability of the ternary complex are key determinants of PROTAC activity, depending on linker length, flexibility, and spatial orientation of the binding domains. However, one of the biggest pharmacological issues is the hook effect: at high concentrations, PROTACs form non-productive binary complexes with either the target or the E3 ligase, reducing degradation efficiency and complicating in vivo dosing.

The field has evolved through distinct generations. Early peptide-based constructs proved the concept of proximity-induced ubiquitination but suffered from poor cell penetration, rapid protease degradation, and low bioavailability. The transition to small-molecule PROTACs created more drug-like molecules with better chemical stability, oral bioavailability, and cellular permeation, enabling degradation of kinases, nuclear receptors, and transcription factors. Nevertheless, even these second-generation molecules had poor pharmacokinetics due to high molecular weight, high lipophilicity, and low metabolic stability, alongside limited tissue selectivity. Third-generation platforms now address these shortcomings: PHOTACs allow light-activated degradation control in space and time; CLIPTACs assemble in cells via click chemistry from membrane-permeable precursors; AUTACs redirect proteins to the autophagy-lysosome pathway; and RIBOTACs mediate selective degradation of RNA targets, critically expanding the scope of targets and cellular compartments.

Breast cancer is a heterogeneous disease with molecular subtypes characterised by expression of estrogen receptor, progesterone receptor, and HER2. In hormone receptor-positive breast cancer, which encompasses roughly seventy percent of cases, standard therapies such as tamoxifen and fulvestrant fail long-term due to ESR1 mutations, receptor amplification, or ligand-independent activation. PROTACs like ARV-471 mitigate these limitations by facilitating prolonged degradation of ERα, including mutant forms resistant to conventional treatments. In triple-negative breast cancer, which lacks all three receptors and has limited treatment options, degradation of BRD4 and CDK4/6 provides a different approach: BRD4 degradation decreases MYC-dependent transcription, while CDK4/6 degradation causes irreversible cell cycle arrest and increased tumour cell apoptosis in preclinical models. In HER2-positive malignancies, resistance often arises from HER2 mutations or truncated isoforms such as p95HER2; PROTACs targeting HER2 degrade both full-length and mutant receptor forms, shutting down kinase-dependent and scaffold activities. Novel degraders against focal adhesion kinase and the immune checkpoint protein PD-L1 combine tumour growth inhibition with immune escape suppression simultaneously.

ARV-471, also known as vepdegestrant, represents a key clinical innovation for hormone receptor-positive breast cancer. Endocrine therapies, including selective estrogen receptor modulators and degraders such as fulvestrant, are regularly hindered by ESR1 transformation, inefficient receptor downregulation, and pharmacokinetic constraints; fulvestrant’s low oral bioavailability and intramuscular injection requirement make long-term management difficult. ARV-471 was rationally designed as a PROTAC driving proteasome-dependent ER destruction via the cereblon E3 ubiquitin ligase. Its catalytic, event-driven pharmacology efficiently depletes ERα, including mutant versions generally resistant to standard therapy, and potently inhibits estrogen-mediated gene expression, tumour growth, and cell proliferation in preclinical pharmacodynamic studies. In xenograft models resistant to fulvestrant, ARV-471 demonstrated potent antitumor activity and therapeutic resilience. Phase I/II clinical trials revealed a favourable safety profile and therapeutic benefit in patients with metastatic hormone receptor-positive breast tumours who had received extensive pretreatment, including prior endocrine therapy and CDK4/6 inhibitors.

PROTAC molecular design involves a complex relationship among the warhead, the recruited E3 ligase, and the linker. Potency must be optimised alongside selectivity, pharmacokinetics, and cell permeability. Unlike conventional inhibitors, PROTAC warheads need only transient associations with the target to initiate ubiquitination, but poorly designed warheads risk off-target effects or ineffective ternary-complex formation. Computational tools increasingly estimate warhead binding affinity and orientation within the ternary complex, enabling selective targeting of protein isoforms or mutant variants. The linker determines the overall geometry and stability of the ternary complex; its length, flexibility, and composition affect degradation efficiency and metabolic stability. Innovations including PEGylation, alkyl chain optimisation, and cleavable groups aim to balance stability with functional efficiency. Perhaps the most overlooked aspect concerns the E3 ligase component: of over 600 E3 ligases in the human proteome, fewer than ten are routinely used, most commonly cereblon and VHL. This narrow selection limits cellular and tissue targeting, drives resistance or redundancy, and constrains the therapeutic repertoire. Computational virtual screening of E3 ligase pockets against small-molecule collections may expand the ligase toolbox, while antibody-based PROTACs can degrade extracellular or membrane-bound proteins using antigen-specific antibodies conjugated with E3 recruiters.

Despite revolutionary promise, PROTACs face significant limitations in bioavailability, tissue selectivity, toxicity, and off-target effects. Their complexity and large molecular weight diminish pharmacokinetic properties, producing low oral bioavailability and poor membrane permeability. Structural flexibility of the ternary complex contributes to variable degradation profiles that can drive unpredictable toxicity. Off-target degradation is among the most urgent questions: small differences in protein expression localisation may cause unwanted protein degradation, particularly when structurally related off-target proteins are highly expressed in non-pathological tissues, resulting in cytotoxicity or immune activation. Rational optimisation of ternary-complex energetics based on structure-guided modelling may reduce off-target interactions. Tissue-specific delivery remains a major obstacle, as most PROTACs show crude biodistribution. Prodrug-based PROTACs are accelerating in response: these constructs are inactive in the systemic circulation but selectively activated in disease-specific microenvironments, such as in the presence of tumour-associated proteases or acidic pH, localising the degradation effect. Encapsulation in lipid or polymeric nanoparticles is also proving effective, extending circulation half-life and increasing cellular uptake while enabling ligand-mediated delivery to specific cell types.

Translational issues surround in vivo pharmacology, metabolic stability, and efficacy prediction. Enzymatic breakdown, hepatic clearance, and first-pass effects considerably influence PROTAC pharmacokinetics; molecules with high degradation efficacy in vitro often fail to achieve sufficient plasma exposure or tissue distribution in vivo. The physicochemical characteristics of PROTACs, usually high molecular weight combined with lipophilicity, converge in poor water solubility and unpredictable tissue distribution, making formulation challenging and fuelling unpredictable pharmacodynamics. Renal and hepatic clearances do not necessarily cross species, and conventional animal models often fail to recapitulate human-specific enzyme activity or transporter interactions, providing invalid efficacy and toxicity readouts. Standard cell line-based assays fail to mimic the tumour microenvironment and cellular heterogeneity found in patients, breaking the chain of response prediction. In response, organoid systems and patient-derived xenografts offer more physiologically relevant platforms that preserve native tumour structure, gene expression, and microenvironmental interactions, enabling iterative optimisation of PROTACs against clinically relevant endpoints before proceeding to humans.

An emerging frontier concerns PROTAC research targeting pro-metastatic kinases and epithelial-to-mesenchymal transition markers to interfere with invasive and immune-evasive properties. Crosstalk between protein degradation and immune modulation remains understudied, particularly dual-activity mechanisms that degrade oncogenic signalling while activating immune responses. New design approaches target dual-action PROTACs capable of degrading oncogenic drivers such as AXL or SRC while simultaneously attacking PD-L1 or immunosuppressive controls in the tumour microenvironment, potentially rewiring it to an immune-permissive state. Such degraders could be combined with immune checkpoint blockers or cytokine-directed therapies to counter resistance, increase therapy duration, and improve clinical outcomes in metastatic cancer. Overall, PROTACs constitute a revolutionary treatment platform in breast cancer, providing an event-based pharmacological system that overcomes the intrinsic limitations of traditional inhibitors. Their long-term innovation and considered clinical development could transform personalised oncology and offer durable solutions against resistance across the full range of breast cancer subtypes.

Subject of Research: Harnessing the ubiquitin-proteasome system: advances and challenges of PROTACs in breast cancer

Article Title: Harnessing the ubiquitin-proteasome system: advances and challenges of PROTACs in breast cancer

Article References: Fanai, H. L., Babu, B., Rajagopal, K., & Byran, G. (2026). Harnessing the ubiquitin-proteasome system: advances and challenges of PROTACs in breast cancer. Molecular Biology Reports, 53(1), Article 1733. https://doi.org/10.1007/s11033-026-12830-7

Image Credits: AI Generated

DOI: 10.1007/s11033-026-12830-7

Keywords: Harnessing, ubiquitin-proteasome, system, advances, challenges, PROTACs, breast, cancer, scientific research

The research, led by E. Rosette Celsiya Mary and C. Sudandiradoss from Vellore Institute of Technology, systematically compared the binding resilience of first-generation IMiDs against next-generation CELMoDs—including iberdomide, mezigdomide, CC-885, CC-122, and CC-3060—across a panel of structurally prioritized deleterious CRBN variants. The team began by retrieving 409 missense single nucleotide polymorphisms (SNPs) of CRBN from the NCBI dbSNP database and then deployed a battery of functional prediction tools, including PolyPhen-2, PANTHER, MutationTaster, and SNPs & GO, alongside structural stability predictors DynaMut2 and DUET. From this comprehensive screen, six variants located within the CRBN Ubiquitin Ligase Targeting (CULT) domain—residues 318 to 426—emerged as particularly damaging: G344R, N351T, H353R, H357Q, S379I, W380R, and P382R. These residues sit squarely within the thalidomide-binding pocket, the very region that IMiDs and CELMoDs must engage to recruit CRBN into a functional ternary complex with the target protein.

What makes these findings clinically resonant is that several of the identified variants overlap with mutations experimentally documented in IMiD-treated patients. The P382R variant, for instance, has been reported in an IMiD-refractory or relapsed patient, while W380R sits within the most significant thalidomide-binding pocket. Other experimentally characterized variants such as C326Y, associated with pomalidomide refraction, and A347V, linked to lenalidomide resistance, further underscore the vulnerability of this domain. The researchers also noted that G344R was the only high-scoring variant found in the ClinVar database, flagged as a variant of uncertain significance—a detail that reinforces its potential clinical relevance even as most other high-impact variants remain absent from clinical genomic repositories.

To interrogate how these mutations affect ligand binding, the team constructed a homology model of CRBN using MODELLER with the UCSF Chimera 1.19 interface, anchored on a high-resolution crystal structure (PDB ID: 7BQU, resolved at 1.9 Å) and refined against an AlphaFold 2-predicted template. The resulting model achieved 100% sequence identity with the hybrid template, and Ramachandran plot analysis confirmed that approximately 89 to 90 percent of residues occupied favorable regions, with only 5 percent in disallowed zones. With this validated structural foundation in place, the researchers performed molecular docking using GNINA 1.0 integrated with AutoDock Vina, leveraging a convolutional neural network-based scoring function to predict binding affinities across all eight ligands against both wild-type and mutant CRBN proteins.

The docking results were striking. Among all tested compounds, CC-885—a next-generation CELMoD—demonstrated the most potent and consistent binding, with affinity scores ranging from −9.34 to −10.40 kcal/mol across all CRBN variants. Its best predicted affinity of −10.40 kcal/mol against wild-type CRBN substantially outperformed thalidomide (−7.80 kcal/mol), lenalidomide (−7.36 kcal/mol), and pomalidomide (−7.15 kcal/mol). Although CC-885’s ligand efficiency (−0.34) was lower than that of the smaller IMiDs—a consequence of its larger molecular size distributing binding energy across more heavy atoms—its absolute binding strength was unmatched. Mezigdomide and iberdomide occupied an intermediate tier, showing improved performance over traditional IMiDs but falling short of CC-885’s dominance. Notably, mezigdomide exhibited enhanced binding affinity in the S379I (−8.24 kcal/mol) and P382R (−8.15 kcal/mol) mutants compared to wild-type (−7.89 kcal/mol), hinting at some mutation-resilient properties among certain CELMoDs.

Interaction profiling using the Protein Ligand Interaction Profiler (PLIP) revealed that CC-885 engaged in a richer network of non-covalent contacts than its competitors, combining hydrogen bonds, hydrophobic interactions, and π-cation interactions across wild-type and mutant complexes. Residues such as ASP50, SER272, SER339, LEU261, TRP264, ASP265, LEU268, LEU273, and LEU342 featured prominently in these interactions, with LYS269 contributing a π-cation contact. By contrast, pomalidomide relied primarily on hydrogen bonds with ASP50, THR51, ASP265, and LYS269, while mezigdomide showed more variable and sometimes absent interaction patterns across mutants. This richer interaction landscape suggested that CC-885’s larger scaffold might provide a structural buffer against mutation-induced perturbations in the binding pocket.

But static docking alone cannot capture the dynamic reality of protein-ligand recognition. To address this, the team turned to 200-nanosecond molecular dynamics simulations using GROMACS 2025.4 with the CHARMM36 force field, solvating each complex in a dodecahedral box with TIP3P water and 0.15 M NaCl to maintain physiological ionic strength. They focused on the wild-type, S379I, and P382R variants bound to pomalidomide, mezigdomide, and CC-885. The results were unambiguous: CC-885-bound complexes maintained superior conformational stability across triplicate independent simulations, with protein RMSD values ranging from approximately 0.39 to 0.56 nm, radius of gyration values consistently within 2.38 to 2.42 nm, and solvent-accessible surface area values remaining in a narrow band of roughly 230 to 270 nm². In contrast, pomalidomide complexes exhibited higher fluctuations and greater solvent exposure, particularly in the P382R mutant, while mezigdomide complexes showed intermediate behavior with notable ligand mobility in the S379I variant.

Ligand RMSD analysis further cemented CC-885’s advantage. The mean ligand RMSD values for CC-885 complexes ranged from approximately 0.26 to 0.57 nm across replicates, with the P382R mutant displaying particularly consistent ligand positioning. Pomalidomide and mezigdomide, by comparison, exhibited greater structural deviations and increased ligand mobility, with the P382R mutant showing the greatest fluctuation in the pomalidomide-bound complex. Hydrogen bond analysis revealed that CC-885 maintained persistent, continuous interactions throughout all simulation replicates, whereas pomalidomide and mezigdomide showed more intermittent bonding patterns. Molecular Mechanics Poisson-Boltzmann Surface Area (MM/PBSA) calculations confirmed these observations, with CC-885 complexes exhibiting the most favorable binding free energies—reaching approximately −35 to −40 kcal/mol in certain replicates—compared to the weaker affinities of pomalidomide and mezigdomide complexes.

Perhaps most intriguingly, the S379I variant, which the variant impact analysis had classified as stabilizing rather than destabilizing, was confirmed through simulation to enhance protein compactness, as evidenced by consistently lower SASA values and favorable radius of gyration measurements across all ligand-bound complexes. Yet even this stabilizing mutation did not compromise CC-885’s binding performance. The P382R variant, clinically associated with IMiD resistance, showed clear signs of destabilization in the pomalidomide-bound complex—elevated RMSD and SASA values—but remained well-accommodated within the CC-885 binding environment. This differential response underscores a central thesis of the study: the choice of E3 ligase-recruiting ligand can determine whether resistance-causing mutations translate into therapeutic failure or remain structurally tolerated.

The implications of this work extend beyond the immediate finding that CC-885 outperforms first-generation IMiDs in mutation-resilient binding. By systematically mapping the structural consequences of CRBN variants within the CULT domain and demonstrating that next-generation CELMoDs can maintain stable ternary complex architecture despite these perturbations, the study provides a rational framework for future PROTAC design. Rather than treating resistance as an inevitable clinical endpoint, researchers can now consider ligand selection as a proactive strategy to preempt mutation-induced failure. The authors acknowledge that their findings remain at the computational stage and that experimental validation and clinical investigation will be essential to translate these insights into therapeutic practice. Nevertheless, the convergence of variant impact prediction, homology modelling, deep-learning-enhanced docking, and extended molecular dynamics simulation represents a powerful methodological template for identifying mutation-resilient degraders. As PROTAC therapy continues to gain momentum in cancer treatment since its clinical resurgence in 2015, studies like this one illuminate a path toward designing next-generation molecular glues and degraders that can withstand the evolutionary pressure of tumor mutation—turning the very mutations that once conferred resistance into targets for strategic ligand engineering.

Subject of Research: Computational evaluation of next-generation CRBN E3 ligase modulators as alternatives to immunomodulatory drugs for overcoming CRBN mutation-driven resistance in PROTAC therapy

Article Title: CRBN E3 ligase modulators (CELMoDs) as potential alternative for immunomodulatory drug (IMiD) resistance in CRBN-based targeted therapy

Article References: Mary, E. R. C., & Sudandiradoss, C. (2026). CRBN E3 ligase modulators (CELMoDs) as potential alternative for immunomodulatory drug (IMiD) resistance in CRBN-based targeted therapy. Results in Chemistry, 31, Article 103972. https://doi.org/10.1016/j.rechem.2026.103972

Image Credits: AI Generated

DOI: 10.1016/j.rechem.2026.103972

Keywords: PROTACs, CRBN, CELMoDs, IMiDs, drug resistance, molecular docking, molecular dynamics, CC-885, mezigdomide, CULT domain, multiple myeloma, targeted protein degradation

To understand why this matters, it helps to start with PROTACs, or PROteolysis TArgeting Chimeras. These bifunctional molecules are the flagship technology of targeted protein degradation, one of the most exciting areas of modern drug discovery. A PROTAC has two business ends: one binds a protein that scientists want eliminated, and the other recruits an E3 ubiquitin ligase, the cellular machinery that tags unwanted proteins for destruction by the proteasome. By physically dragging the target protein into contact with the ligase, a PROTAC catalyzes the formation of a protein-protein interaction that would never happen naturally, triggering the cell’s own waste-disposal system to chew up the target. Unlike conventional inhibitors, which merely block a protein’s activity and must be present at high concentrations to keep it suppressed, degraders can eliminate the protein altogether and work catalytically, so a single molecule can destroy many copies of its target.

The problem is that this power comes with a loss of control. Because PROTACs act anywhere they reach in the body, they can degrade their target proteins in healthy tissues as well as diseased ones, producing side effects that are difficult to predict. The field has therefore been searching for ways to impose spatiotemporal control, meaning the ability to restrict drug activity to a specific place at a specific time. Light is the most attractive remote trigger for this purpose, since it can be focused on a tissue with exquisite precision and switched on and off at will. Photocaging strategies, in which a light-sensitive chemical group masks a drug’s activity until illumination releases it, have been applied to PROTACs before, but earlier systems suffered from weak contrast between the dark and illuminated states, or required high-energy ultraviolet light that damages cells and penetrates poorly into tissue.

The team behind the new work, led by Dmytro Havrylyuk, David K. Heidary and Edith C. Glazer at North Carolina State University, together with colleagues at the University of Kentucky, took a different approach by building the light switch out of a metal. Their RuPHOTACs use ruthenium(II) coordination complexes as photocages wrapped around the PROTAC scaffold. Ruthenium complexes have a distinctive photochemistry: when they absorb light, they can undergo ligand photodissociation, cleanly releasing the molecule attached to the metal. Crucially, the absorption properties of these complexes can be tuned so that the release is driven by low-energy red light rather than damaging ultraviolet wavelengths. Red light penetrates deeper into biological tissue and is far gentler on living cells, which is why the authors emphasize that their systems are optimized for biological applications rather than merely demonstrated in a cuvette.

To prove the concept, the researchers targeted bromodomain-containing proteins, a family of epigenetic regulators that read acetylation marks on histones and help control gene expression. These proteins, particularly members of the BET family, are major targets in cancer research because many tumors depend on them to drive the expression of growth-promoting genes. In the dark, the ruthenium cage keeps the RuPHOTAC inert; when illuminated with red light, the cage releases the active degrader, which then recruits the E3 ligase and drags the bromodomain protein to the proteasome. The team showed that the compounds strongly reduced not only the levels of the bromodomain targets themselves but also the abundance of two important downstream proteins, c-MYC and PIM1, both of which are transcriptional targets of BET proteins and both of which are heavily implicated in cancer progression. Knocking down c-MYC in particular is a longstanding goal in oncology, since the protein has been notoriously difficult to drug with conventional small molecules.

The quantitative performance of the new compounds is what sets the study apart. The authors report that the RuPHOTACs achieve the highest selectivity for activation in the light versus the dark reported for photocontrolled degraders, meaning that in the absence of light the molecules are essentially silent, while a brief illumination unleashes full degrading activity. They also show improved potency against the target proteins compared with prior systems, so less compound is needed to achieve the same degree of degradation. Most strikingly, the increased efficacy extends to animal work: using low-energy red light, the team demonstrated increased efficacy in vivo, a critical benchmark because many photochemical technologies that shine in cell culture fail when confronted with the optical and biological complexity of a living organism.

Measuring protein degradation sounds simple but is surprisingly tricky, and the study introduces an elegant solution to a chronic measurement problem. Traditional assays often rely on antibodies or fluorescent tags that report total protein abundance, but those signals conflate two opposing processes: the destruction of existing protein molecules and the continuous production of new ones. If a drug slows protein synthesis as a side effect, or if the cell ramps up production to compensate for degradation, the apparent degradation rate becomes distorted. To disentangle these effects, the researchers created fusion proteins in which the target of interest is fused to Dendra2, a photoconvertible fluorescent protein. Dendra2 can be switched from a green to a red fluorescent state by light, allowing the researchers to mark a defined cohort of pre-existing protein molecules and then watch that cohort disappear over time as the PROTAC does its work.

This bifunctional reporter system offers several advantages over previously described PROTAC reporters. Because the photoconverted molecules are already synthesized, any change in the red fluorescence signal reflects true degradation rather than changes in new protein production. At the same time, the green signal tracks newly synthesized protein, so the researchers can monitor both destruction and replenishment simultaneously in the same living cell. Importantly, the approach does not perturb translation, proteostasis, or cell health, meaning the measurements reflect normal cellular physiology rather than artifacts introduced by the measurement itself. The authors argue that this makes the system superior to prior reporter strategies for live-cell analysis of protein degradation, and it could become a standard tool for the broader targeted degradation community, which has long struggled with assay artifacts.

The study also carries a broader message about the role of metals in chemical biology. Ruthenium is not a component of any natural biomolecule, and metal complexes are often viewed with suspicion in drug development because of concerns about stability and toxicity. Yet the work demonstrates that incorporating a metal component within an organic PROTAC confers multiple concrete advantages: a clean and efficient photorelease mechanism, absorption profiles compatible with low-energy red light, and tunable photophysical properties that organic photocages struggle to match. The researchers suggest that this design philosophy, using coordination chemistry as an engineering platform for light-controlled drugs, could extend well beyond the specific bromodomain targets validated here, potentially allowing any PROTAC scaffold to be fitted with a ruthenium switch.

Caveats remain, as they always do at this stage of translation. The work was supported by the National Institutes of Health and the Kentucky Cabinet for Health and Family Services, and the authors declare no competing interests, but moving from validated compounds in cells and animal models toward clinical candidates will require extensive safety evaluation of the ruthenium payloads, optimization of light delivery to internal organs, and pharmacokinetic studies that the current paper does not address. The article itself was shared early as a peer-reviewed accepted manuscript subject to further editorial processing. Even so, the combination of near-total dark-state silence, red-light activation, in vivo efficacy, and a genuinely improved measurement technology makes RuPHOTACs one of the most complete demonstrations to date that protein degradation can be placed under remote optical control. For a field racing to make degraders safer and more precise, that is a result worth watching closely.

Subject of Research: Light-activated ruthenium photocaged PROTACs for spatiotemporally controlled targeted protein degradation

Article Title: RuPHOTACs provide photocontrol over protein degradation with optimized properties for biological applications

Article References: Havrylyuk, D., LaMore, A. P., Al-Hamaly, M. A., Blackburn, J. S., Heidary, D. K., & Glazer, E. C. (2026). RuPHOTACs provide photocontrol over protein degradation with optimized properties for biological applications. Nature Communications. https://doi.org/10.1038/s41467-026-78110-x

Image Credits: AI Generated

DOI: 10.1038/s41467-026-78110-x

Keywords: targeted protein degradation, PROTACs, RuPHOTACs, ruthenium photocages, photochemistry, E3 ubiquitin ligase, bromodomain proteins, c-MYC, Dendra2 reporter, red light activation, chemical biology, cancer research

The review, led by researchers at West China Hospital of Sichuan University, is notable for its insistence on rigor. The authors point out that while aberrant condensate behavior is increasingly implicated in cancer, many intracellular assemblies that have been attributed to LLPS have not been validated using strict experimental criteria. This matters because the cell contains many different ways of organizing matter: stable enzymatic complexes, scaffold-driven assemblies, polymer networks, and gel-like aggregates can all look like droplets under a microscope without being true liquid phases. A true LLPS droplet typically forms through weak, multivalent interactions among intrinsically disordered regions of proteins, fuses and relaxes like a liquid, exchanges components dynamically with the surrounding dilute phase, and dissolves predictably when conditions such as salt concentration, temperature, or protein concentration change. The review lays out an evidence-oriented framework for applying these criteria before labeling a structure a phase-separated condensate, a discipline the authors say the cancer field urgently needs.

At the biophysical level, condensate formation depends on a set of molecular determinants that the review examines in detail. Intrinsically disordered regions, or IDRs, are stretches of protein sequence that do not fold into a single rigid structure but instead sample many conformations. These regions carry distributed motifs—charged blocks, aromatic residues, proline-rich motifs, and arginine-glycine rich elements—that engage in multiple weak, transient interactions with one another. When the combined valence and strength of these interactions cross a threshold, the molecules demix into a dense phase enriched in those components and a dilute phase depleted of them. RNA, multivalent scaffolding proteins, and post-translational modifications such as phosphorylation, methylation, SUMOylation, and O-GlcNAcylation all tune where that threshold sits. The result is that a cell can, in principle, switch entire condensates on or off, reshape their composition, alter their viscosity, or harden them into less dynamic states without synthesizing new proteins—a degree of regulatory control that conventional signaling pathways cannot match.

Cancer exploits this control system in several ways, and the review systematically catalogues them. Mutations can add, remove, or charge-flip residues within disordered regions, shifting the phase boundary so that droplets form at concentrations where healthy cells never condense. Chromosomal translocations generate fusion proteins that stitch together a DNA-binding domain with a prion-like disordered domain, a combination notorious for driving condensate formation at oncogenic loci. Altered post-translational modification patterns, changes in RNA abundance, shifts in metabolic state, and the crowded, hypoxic, acidic environment of a tumor can all push condensates past their saturation point. The unifying theme, according to the authors, is that tumor cells do not need to invent new molecular machines; they can repurpose an existing physical mechanism of cellular organization and tilt it toward growth, survival, and spread.

The functional consequences are evaluated across five major domains of cancer biology. The first is signaling and transcription. Phase separation offers a mechanistic explanation for how transcription factors, co-activators, and the RNA polymerase machinery concentrate at specific genomic loci to form transcriptional hubs, and how signaling receptors cluster at membranes to amplify weak extracellular signals. If a tumor amplifies or mutates the multivalent components of these hubs, the hubs can become hyper-condensed, locking oncogenic programs into a permanently active state. The second domain is genome maintenance, where condensates are implicated in the response to double-strand breaks, in heterochromatin organization, and in the sequestration of repair factors. Condensate dysregulation here can either blunt DNA repair, promoting mutation accumulation, or paradoxically protect tumor cells from genotoxic therapies by concentrating repair machinery at damage sites.

The third and fourth domains—metastasis with cellular plasticity and tumor immunity—illustrate how condensate physics reaches beyond the nucleus. The review discusses how phase-separated assemblies participate in the epithelial–mesenchymal transition, cytoskeletal remodeling, and extracellular vesicle biology that enable tumor cells to detach, survive in circulation, and colonize distant tissues. On the immunity side, condensates shape the antigen presentation machinery, the formation of immune synapses in T cells, the behavior of stress granules during interferon signaling, and the cGAS–cGAMP–STING-type innate sensing pathways that determine whether a tumor looks like a threat to the immune system. A condensate that sequesters double-stranded RNA or dampens interferon-stimulated gene expression can effectively switch off the molecular alarm bells that would otherwise recruit cytotoxic T cells and natural killer cells to the tumor.

The fifth domain, therapeutic resistance, ties these mechanisms to the clinic. The review evaluates evidence that condensate formation contributes to resistance against tyrosine kinase inhibitors, PARP inhibitors, and androgen receptor pathway inhibition, among other therapies. The proposed mechanisms include the physical sequestration of drugs within dense phases, the concentration of drug targets into compartments where inhibitor penetration is poor, the buffering of inhibited pathways by condensate-stored reserves of signaling molecules, and stress granule–mediated survival programs that keep cells alive long enough to evolve durable resistance. Because these are physical, population-level phenomena rather than single gene mutations, they may explain forms of resistance that genomic sequencing alone cannot predict—adding a spatial and material dimension to the pharmacology of cancer treatment.

Perhaps the most forward-looking portion of the review concerns condensate-directed therapeutic strategies, which the authors assess explicitly according to the strength of their experimental and clinical evidence. Several classes of approach are now in play. Small molecules that partition into specific condensates can disrupt or remodel them; some such molecules have already demonstrated that selective condensate modulation is chemically achievable. Proteolysis-targeting chimeras, or PROTACs, can be designed to degrade the scaffold proteins or IDRs around which oncogenic condensates assemble. Oligonucleotide therapeutics can target the RNAs that nucleate pathological droplets. Nanoparticle platforms, including engineered particles designed to home in on and perturb specific condensates, represent a delivery-oriented strategy. The authors’ verdict, however, is deliberately cautious: the overwhelming majority of this work remains preclinical. Demonstrating that a compound dissolves a droplet in a test tube, or even in a cell line, is a long way from showing that it shrinks tumors in patients without dissolving the healthy condensates that normal cells depend on.

That caveat reflects the central challenge the review identifies for the field: specificity and validation. Cells are full of condensates that perform essential functions in nucleolar assembly, ribosome biogenesis, RNA processing, and stress adaptation, so a broadly acting condensate disruptor risks toxicity through collateral damage. Experimental validation remains difficult because phase separation in living cells is hard to prove unambiguously; methods such as live-cell imaging of fusion events, fluorescence recovery measurements, optogenetic control of multivalency, and proximity labeling are powerful but each carries its own artifacts. The authors also flag the conceptual danger of overextension, noting that the umbrella term biomolecular condensation covers a broader range of mechanisms and material states than LLPS proper, and that blurring the distinction has led the literature into claims that later scrutiny could not support. Their framework asks researchers to state which process they are actually observing and to apply matching criteria.

What emerges from the review is both a warning and a promise. The warning is that the condensate-cancer literature contains a mixture of rigorously validated LLPS mechanisms and incompletely characterized assemblies, and that therapeutic enthusiasm should be calibrated accordingly. The promise is that a genuine physical principle underlies a strikingly wide range of malignant behaviors—from oncogenic transcription to immune evasion to drug resistance—and that principle, unlike a mutation, is in principle reversible by changing the chemical environment of the cell. If the field can agree on how to prove that a droplet is a droplet, and if chemistry can deliver molecules that reshape only the condensates that matter, the energy stored in a decade of condensate biology may yet translate into the next generation of cancer therapeutics. For now, as the authors conclude, the potential remains predominantly preclinical, and the framework they propose is intended to make sure that the path from droplet to drug is followed with the same rigor that the physics itself demands.

Subject of Research: The role of liquid–liquid phase separation and biomolecular condensates in cancer mechanisms and therapy

Article Title: Liquid–liquid phase separation in cancer: mechanisms, biological functions, and therapeutic perspectives

Article References: Tang, P., Li, Y., Huang, C., Xiong, Y., Li, Y., Zhang, T., & Zhang, C. (2026). Liquid–liquid phase separation in cancer: mechanisms, biological functions, and therapeutic perspectives. Molecular Cancer. https://doi.org/10.1186/s12943-026-02798-0

Image Credits: AI Generated

DOI: 10.1186/s12943-026-02798-0

Keywords: liquid–liquid phase separation, biomolecular condensates, cancer biology, intrinsically disordered regions, therapeutic resistance, transcriptional condensates, tumor immunity, metastasis, PROTACs, drug discovery, Molecular Cancer, condensate dysregulation

The fundamental insight behind PROTACs is deceptively simple: instead of blocking a disease-causing protein, destroy it outright. Classical small-molecule drugs operate through what pharmacologists call occupancy-driven inhibition, meaning they must remain bound to their target to exert effect. This strategy struggles against proteins that lack a well-defined binding pocket, even when those proteins are powerful drivers of disease. PROTACs sidestep the problem entirely by hijacking the ubiquitin-proteasome system, the cell’s own garbage disposal machinery. These heterobifunctional molecules carry two business ends, one ligand that grips the target protein and another that recruits an E3 ubiquitin ligase, connected by a chemical linker. When the chimera brings both proteins into proximity, the ligase tags the target with chains of ubiquitin, the universal molecular death mark, and the 26S proteasome chews the protein into peptides.

The mechanistic details matter enormously for drug design. The human genome encodes roughly two E1 ubiquitin-activating enzymes, about forty E2 conjugating enzymes, and more than six hundred E3 ligases, offering enormous untapped selectivity potential. Crucially, PROTAC action is catalytic rather than stoichiometric: a single degrader molecule can, in principle, drive the elimination of many copies of its target, dissociating after each degradation cycle to find another. But productive destruction depends on forming a stable three-body complex between target, degrader, and ligase, a property known as ternary complex cooperativity. Studies of the BRD4 degrader MZ1 using surface plasmon resonance and crystallography have shown that longer ternary complex residence time correlates with more efficient ubiquitination, and that high cooperativity allows MZ1 to selectively degrade BRD4 while sparing its close relatives BRD2 and BRD3. There is also a pharmacological quirk that developers must respect: at high concentrations, PROTACs can saturate either protein separately, collapsing ternary complex formation and paradoxically reducing degradation. This bell-shaped dose-response behavior, known as the hook effect, complicates dose selection in ways conventional inhibitors never face.

The design of these molecules is a delicate balancing act across three structural elements. Target ligands need not maximize binding affinity, since moderate affinity often suffices when the ternary complex is cooperative and geometrically productive, but they must tolerate the added bulk of a linker without losing selectivity. On the ligase side, cereblon, or CRBN, and von Hippel-Lindau, or VHL, dominate the field because high-quality ligands exist for both. CRBN recruiters derived from thalidomide, lenalidomide, and pomalidomide benefit from a favorable medicinal chemistry profile, while VHL ligands built around a stereochemically defined hydroxyproline core, exemplified by the nanomolar-affinity probe VH298, often deliver stable ternary complexes with fewer off-target effects on natural cereblon substrates. Emerging ligases including KEAP1, RNF114, and DCAF family proteins may eventually enable tissue-selective degradation, though most remain hampered by limited ligand availability and incomplete structural characterization. Linker engineering ties everything together: too short and the complex is strangled, too long and entropy penalties mount, and subtle modifications such as methyl substitution have been shown to improve oral absorption while preserving degradation efficiency.

Nowhere is the platform’s promise more visible than in oncology, where cancer cells’ dependence on a handful of overexpressed or mutant proteins makes them ideal targets for elimination. ARV-110, also known as bavdegalutamide, is an orally bioavailable androgen receptor degrader designed for metastatic castration-resistant prostate cancer patients who have stopped responding to conventional antagonists like enzalutamide. Early phase 1/2 data revealed encouraging activity in a molecularly defined subgroup: patients whose tumors carried AR mutations T878 or H875 showed a prostate-specific antigen fifty percent response rate of approximately forty-six percent. Yet the drug’s limitations are instructive, since it fails to degrade the common resistance variant AR-V7 or the L702H mutation, and gastrointestinal side effects such as nausea and diarrhea have accompanied its use. The lesson, the review emphasizes, is that clinical efficacy depends not only on degradation itself but on biomarker-guided patient selection rooted in the molecular subtype of each tumor.

On the breast cancer front, ARV-471, known as vepdegestrant, has advanced furthest of all PROTACs. Developed for ER-positive, HER2-negative advanced breast cancer, the molecule eliminates both wild-type and mutated estrogen receptors, including the notoriously difficult ESR1 mutations that drive endocrine resistance. Preclinical studies showed deeper ER knockdown than fulvestrant, the traditional selective estrogen receptor degrader, and clinical phase 1/2 results demonstrated robust activity with a manageable safety profile in heavily pretreated patients. Researchers identified 200 milligrams once daily as the optimal dose for balancing efficacy and tolerability, and the compound is now being evaluated in the global phase 3 VERITAC-2 trial, a milestone marking one of the first PROTACs to reach late-stage development for solid tumors. Published results in the New England Journal of Medicine have confirmed the approach’s clinical credibility.

Blood cancers have yielded another compelling success story. Bruton’s tyrosine kinase inhibitors such as ibrutinib frequently lose effectiveness when tumors acquire the C481 mutation, which prevents covalent binding to the kinase’s active site. BTK degraders work where inhibition fails because they do not depend on sustained occupancy of any single pocket; they remove the entire protein, abolishing both enzymatic activity and the oncogenic scaffolding functions that can persist even when the kinase is silenced. NX-2127, an oral cereblon-recruiting degrader, eliminates wild-type and C481-mutant BTK alike, and uniquely also degrades the immunomodulatory transcription factors IKZF1 and IKZF3, potentially amplifying anti-tumor efficacy through T-cell activation. Whether this dual action translates into durable benefit without excessive immunological toxicity remains an open question that ongoing trials must answer.

Beyond cancer, the review surveys emerging frontiers that could dramatically widen the platform’s reach. Neurodegenerative diseases are particularly attractive because they are driven by toxic, aggregation-prone proteins such as tau that may be better addressed by removal than inhibition, although the blood-brain barrier imposes punishing constraints on molecular size, polarity, and efflux susceptibility. Recent work with neurotransmitter-derived lipidoid nanoparticles carrying tau-targeting PROTAC-DNA nanocomplexes has promoted tau clearance and cognitive recovery in disease models. In immunology, degraders of IRAK4 and STAT family proteins promise cleaner modulation of inflammatory signaling than reversible inhibitors, and early clinical candidates such as KT-474 are already in testing. Meanwhile, photoactivatable PROTACs offer spatial and temporal control over degradation, antibody-directed delivery systems could solve tissue penetration problems, and macrocyclic degrader designs are shrinking the molecules’ daunting physicochemical footprint.

Substantial obstacles remain before targeted protein degradation can fulfill its promise. Most clinically investigated PROTACs occupy beyond-rule-of-five chemical space with molecular weights between roughly 700 and 1200 daltons, creating persistent difficulties with solubility, passive permeability, metabolic stability, and oral bioavailability. Resistance mechanisms are already appearing, including altered E3 ligase expression, impaired proteasome function, target protein mutations, and compensatory signaling pathways, prompting development of ligase-switching strategies, dual-target degraders, and rational combinations. Manufacturing is its own headache, since assembling two pharmacophores through a linker while preserving stereochemical purity complicates scale-up and inflates costs, argues for early integration of process chemistry and Quality-by-Design principles. Formulation science, from cyclodextrins to lipid nanoparticles and solid dispersions, is being marshaled to rescue otherwise marginal candidates. Artificial intelligence and machine learning are increasingly deployed for ternary complex prediction and linker selection, though docking scores alone cannot yet reliably forecast degradation efficiency and must be validated against biophysical measurements.

The overarching conclusion of the review is that PROTACs now constitute a genuinely distinct pharmacological modality whose success demands simultaneous optimization of ternary complex cooperativity, degrader pharmacokinetics, and tissue-selective ligase recruitment, rather than simple pursuit of binding affinity. The strongest clinical evidence remains concentrated in hormone-driven cancers, but the conceptual reach of the platform extends to proteins that traditional drugs simply could not touch. If the field can deliver ligandable E3 ligases beyond cereblon and VHL, predictable degradation through computational design, orally bioavailable degraders, and validated pharmacodynamic biomarkers that track target loss directly, targeted protein degradation may graduate from elegant chemical biology tool to a foundational pillar of twenty-first-century medicine.

Subject of Research: PROTAC-mediated targeted protein degradation for drug discovery and clinical development

Article Title: Proteolysis targeting chimeras for drug discovery from mechanistic basis to clinical translation

Article References: Badadhe, S. G., Gawali, V. B., Bhalsing, M. D., & Jangme, C. (2026). Proteolysis targeting chimeras for drug discovery from mechanistic basis to clinical translation. Discover Chemistry, 3(1), Article 505. https://doi.org/10.1007/s44371-026-00963-4

Image Credits: AI Generated

DOI: 10.1007/s44371-026-00963-4

Keywords: PROTACs, targeted protein degradation, ubiquitin-proteasome system, E3 ligase, medicinal chemistry, bavdegalutamide, vepdegestrant, NX-2127, ternary complex cooperativity, hook effect, oncology drug development, beyond-rule-of-five

The new review, authored by Shun-Ran Li, Meng-Qian Yu, and colleagues at Hangzhou Normal University and collaborating institutions, systematically surveys the explosion of dual- and multi-target degraders reported between 2023 and 2026. Its central premise is that complex diseases rarely depend on a single molecular culprit. Cancer and neurodegenerative disorders are governed by redundant and compensatory signaling networks, so when one driver protein is eliminated, others rush to fill the gap. Conventional single-target PROTACs, however powerful, can be undermined by this biological backup system. Dual PROTACs attempt to solve the problem in a single chemical entity, collapsing what would otherwise be a combination of two drugs into one compound with one set of pharmacokinetics.

The authors organize the growing catalog of dual degraders into two broad design classes. The first targets homologous proteins within the same family, where structural similarity can be exploited by a single warhead that binds both. Cyclin-dependent kinases have been a particular focus, with dual degraders reported for CDK4/6, CDK2/5, and CDK12/13, the latter exemplified by the orally bioavailable triple-negative breast cancer candidate DN1679. The BCL-2 family of apoptosis regulators has yielded dual BCL-2/BCL-xL degraders with improved anti-leukemic activity, and the field has now seen first-in-class degraders for the bromodomain proteins BAZ2A and BAZ2B as well as dual histone deacetylase degraders, including HDAC3/HDAC8 molecules that revealed new roles for histone acetylation in gene regulation.

The second, and pharmacologically more ambitious, class targets two distinct proteins sitting on different but interconnected disease pathways. Here the review catalogues an impressive roster: ERα/aromatase degraders designed to overcome endocrine-resistant breast cancer by hitting both the receptor and the enzyme that produces its activating estrogen; α-synuclein/tau degraders aimed at the protein aggregates that define Parkinson’s and Alzheimer’s disease; BET/HDAC and CBP/BRD4 degraders that combine epigenetic readers and erasers in one molecule; PI3K/mTOR degraders that suppress the entire eponymous survival pathway; and FLT3/CHK1 degraders that pair an oncogenic kinase with a checkpoint kinase to attack acute myeloid leukemia from two directions.

The technical heart of the review lies in its dissection of structure-activity relationships. Linker chemistry is where dual PROTACs live or die. Because a single molecule must accommodate two target-binding events, the linker length, attachment point, and flexibility determine not only potency but the ternary geometry between target, PROTAC, and E3 ligase that licenses ubiquitin transfer. Several case studies illustrate the point. Dual BCL-xL/BCL-w degraders were built by exploiting the bis(sulfonyl)benzene ring of the clinical inhibitor ABT-263 as a linkage vector, showing how careful warhead decoration can convert a blocker into a degrader. In the FLT3/CHK1 program, systematic linker scans revealed how marginal changes in length flipped degradation selectivity between the two kinases. The authors emphasize that hook effects, hook-like concentration dependence in which excess PROTAC saturates both binding sites separately and aborts the ternary complex, remain a persistent design trap requiring careful dose-response characterization.

E3 ligase selection emerges as another decisive variable. Most reported dual degraders recruit either the von Hippel-Lindau (VHL) ligase or cereblon (CRBN), reflecting the maturity of their ligand chemistries. CRBN-recruiting degraders derived from pomalidomide and related immunomodulatory drugs have proven especially productive for kinases and transcriptional regulators, while VHL ligands dominate among cytosolic and nuclear targets. But the review is blunt about the field’s narrow toolkit: the reliance on just two or three E3 ligases limits tissue selectivity, constrains the design space for dual targets, and contributes to off-target degradation of neo-substrates such as IKZF1 and IKZF3. Expanding the E3 ligase repertoire, including tumor-selective or tissue-specific ligases, is flagged as a priority for next-generation design.

Among the milestones the review highlights are the first dual degraders aimed at non-kinase epigenetic regulators and, strikingly, at protein aggregates themselves. Degraders capable of clearing α-synuclein and tau aggregates simultaneously represent a conceptual breakthrough for neurodegeneration, because both misfolded proteins cross-seed one another and together drive pathology in diseases such as dementia with Lewy bodies and Alzheimer’s. The authors note that these designs repurposed aggregation-binding scaffolds, such as thioflavin-derived amyloid ligands, as warheads, demonstrating that even supramolecular pathological assemblies can be brought into the reach of the ubiquitin-proteasome system. In parallel, dual GSPT1/BRD4 degraders exploit cereblon-mediated translational termination factor degradation alongside epigenetic transcriptional collapse to kill leukemia cells through mechanistically independent routes.

The translational horizon is coming into view. The first PROTAC, vepdegestrant, has moved targeted degradation into approved oncology practice, and clinically advanced single-target degraders have validated the modality’s core principles. Dual degraders now face the harder test of converting dual potency into dual efficacy with an acceptable safety profile. The review identifies pharmacokinetics as the chief obstacle: dual PROTACs are large, often exceeding the classic rule-of-five boundaries for oral absorption, and their high polarity and molecular weight challenge permeability, metabolic stability, and brain penetration. Off-target toxicity arising from polypharmacology is a second concern, since the same warhead promiscuity that enables dual engagement can degrade unintended proteins. Strategies such as introducing one-carbon bridges to lower lipophilicity, incorporating molecular glue features into PROTAC scaffolds, and exploiting CD36-mediated endocytosis to improve cellular uptake are among the emerging countermeasures surveyed.

What the review ultimately delivers is a map. By consolidating the 2023 to 2026 literature into a coherent framework of homologous versus cross-pathway dual targets, and by extracting transferable SAR lessons on warhead choice, linker optimization, and E3 ligase pairing, the authors have given medicinal chemists a practical playbook for the next round of design. If the remaining pharmacokinetic and selectivity problems can be tamed, dual PROTACs could compress combination therapy into a single pill, offering patients with complex, drug-resistant diseases a weapon that dismantles two pillars of pathology at once. For a field that has already taught medicine to delete proteins rather than merely inhibit them, degrading disease networks two nodes at a time may be the logical, and inevitable, next act.

Subject of Research: Development of dual PROTACs that simultaneously degrade two disease-related proteins for therapeutic applications in cancer and neurodegenerative disease.

Article Title: Recent advances of dual PROTACs for potential therapeutic applications

Article References: Li, S.-R., Yu, M.-Q., Du, B.-Q., Jin, K.-J., Chen, S.-X., Hui, Z., Zhang, H., Mao, N.-D., Gao, Y., & Ye, X.-Y. (2026). Recent advances of dual PROTACs for potential therapeutic applications. Molecular Diversity. https://doi.org/10.1007/s11030-026-11734-9

Image Credits: AI Generated

DOI: 10.1007/s11030-026-11734-9

Keywords: PROTACs, targeted protein degradation, dual degraders, ubiquitin-proteasome system, E3 ubiquitin ligase, cancer therapy, neurodegenerative disease, BCL-2, BRD4, CDK inhibitors, structure-activity relationships, drug discovery

Resistance arises through sophisticated cellular adaptations, including isoform switching of BRD4 and activation of compensatory signaling pathways such as PI3K/AKT and WNT. This resistance, coupled with the intricate transcriptional circuitry characteristic of solid tumors—distinct from hematological malignancies—has dampened hopes for BET inhibitors as monotherapies.

To address these challenges, the field is now pivoting towards next-generation strategies with enhanced specificity and efficacy. Among these, BD2-selective inhibitors aim to spare BD1, effectively reducing hematologic toxicities while maintaining robust anti-tumor effects. Proteolysis targeting chimeras (PROTACs) like ARV-771 and MZ1 have gained attention for their ability to degrade BET proteins entirely, potentially circumventing resistance associated with isoform variability.

Further innovation includes bivalent BET inhibitors that simultaneously engage both bromodomains, amplifying binding affinity and tumor suppression. Researchers are also exploring dual-function inhibitors that target BET proteins alongside kinases or histone deacetylases, as well as agents that disrupt BRD4-mediated phase separation at super-enhancers—critical hubs of oncogenic transcription.

Combination therapies represent a vital avenue to amplify therapeutic efficacy. Pairing BET inhibitors with PARP inhibitors has shown synergistic effects by exploiting DNA repair vulnerabilities, particularly in triple-negative breast and ovarian cancers. Similarly, combining BET inhibitors with androgen receptor antagonists improves outcomes in castration-resistant prostate cancer. Immune checkpoint inhibition in conjunction with BET targeting displays promising preclinical results, although toxicity remains a significant concern.

Clinical trials underscore both the potential and hurdles of BET inhibition. Agents like molibresib exhibited measurable activity in NUT carcinoma but required intermittent dosing to manage toxicity. Combinations such as ZEN-3694 with enzalutamide or talazoparib indicate early clinical signals of benefit, but many studies have been discontinued due to limited single-agent activity and pharmacokinetic limitations.

Looking forward, prioritizing the development of highly selective BET degraders, integrating predictive biomarkers such as MYC amplification or BRD4 dependency, and refining combination regimens stand as critical imperatives. Optimizing dosing to mitigate hematological adverse effects will be essential to unlock the full potential of BET-targeted therapies.

In summary, targeting BET proteins in solid tumors remains a vibrant and evolving frontier. First-generation inhibitors laid the conceptual groundwork, but overcoming inherent resistance and toxicity demands innovative next-generation molecules and strategic combinations. The path ahead hinges on biomarker-driven clinical trials and a deeper mechanistic understanding to translate this epigenetic vulnerability into tangible patient benefit.

Subject of Research: BET protein inhibition in solid tumors
Article Title: Inhibition of Bromodomain and Extra-Terminal Domain Proteins in Solid Tumors: Advances, Challenges, and Future Directions
News Publication Date: 2025
Web References: http://dx.doi.org/10.14218/GE.2025.00067
Keywords: BET proteins, BRD4, solid tumors, oncogenic transcription, PROTACs, BD2-selective inhibitors, combination therapy, drug resistance